Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708
Launched by BAYLOR COLLEGE OF MEDICINE · Mar 31, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708," is studying how a condition known as osteogenesis imperfecta (OI) affects the lungs and overall breathing in people with this disorder. OI is often called "brittle bone disease" because it causes bones to be fragile, but it also impacts other connective tissues in the body, including those in the lungs. Since breathing problems can be a serious issue for individuals with OI, researchers want to learn more about why these lung issues occur and how they relate to the condition.
To participate in this trial, you need to be at least 18 years old and have a diagnosis of OI, either through medical evaluation or genetic testing. The study is open to both men and women of all backgrounds. If you join the trial, you will work with a team of healthcare professionals who will monitor your health and help gather important information about how OI affects your lungs. It's important to know that if you have a recent respiratory illness or other serious lung conditions, you may not be eligible to participate. This trial is currently recruiting participants, and your involvement could help improve understanding and treatment options for others with this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals who are able to give informed consent or have a legally authorized representative capable of giving consent on the subject's behalf
- • Individuals ages 18 and older of all races and sexes
- • Individuals who have been diagnosed with OI clinically and/or genetically
- Exclusion Criteria:
- • Individuals diagnosed with respiratory illness within 6 weeks of enrollment or undergoing diagnostic studies for an active illness.
- • Individuals with other skeletal dysplasia or genetic diagnosis
- • Individuals diagnosed with cardiopulmonary comorbidities that affect lung compliance
About Baylor College Of Medicine
Baylor College of Medicine is a leading academic institution dedicated to advancing health through innovative research, education, and clinical care. Located in Houston, Texas, it is renowned for its commitment to excellence in medical education and translational research, fostering collaborations that bridge laboratory discoveries with clinical application. As a clinical trial sponsor, Baylor College of Medicine leverages its robust infrastructure, interdisciplinary expertise, and access to diverse patient populations to conduct cutting-edge clinical studies aimed at improving patient outcomes and enhancing therapeutic approaches across a wide range of medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Los Angeles, California, United States
Los Angeles, California, United States
Baltimore, Maryland, United States
Patients applied
Trial Officials
Vernon Sutton, MD
Principal Investigator
Baylor College of Medicine
Kathleen Raggio
Study Chair
Hospital for Special Surgery, New York
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials